{"id":849715,"date":"2025-05-12T02:03:10","date_gmt":"2025-05-12T06:03:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-participate-in-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference-at-nasdaq\/"},"modified":"2025-05-12T02:03:10","modified_gmt":"2025-05-12T06:03:10","slug":"nanobiotix-to-participate-in-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference-at-nasdaq","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-participate-in-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference-at-nasdaq\/","title":{"rendered":"Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ"},"content":{"rendered":"
\n

PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) — NANOBIOTIX<\/a> (Euronext: NANO \u2013\u2013 NASDAQ: NBTX \u2013 the \u2018\u2018Company<\/strong>\u2019\u2019), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference:<\/p>\n

\n H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ <\/strong>
\n
Date: Tuesday, May 20, 2025
Time: 5:00\u00a0pm EDT \/ 11:00\u00a0pm CEST
Location: New York, NY
Presenters: Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix
Webcast link: Click here<\/a><\/p>\n

The fireside chats will be webcast live from the events page<\/a> of the Investors section of the Company\u2019s website. The replay of the webcast will be available following the event.<\/p>\n

\n About NANOBIOTIX<\/strong>\n <\/p>\n

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company\u2019s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.<\/p>\n

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.<\/p>\n

Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.<\/p>\n

For more information about Nanobiotix, visit us at www.nanobiotix.com<\/a> or follow us on LinkedIn<\/a> and Twitter<\/a><\/p>\n

\n Contacts<\/strong>\n <\/p>\n\n\n\n\n\n
\n Nanobiotix<\/em>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\n
\n
Communications Department<\/strong>
\n
\n Brandon Owens<\/em>
\n
\n VP, Communications<\/em>
\n
+1 (617) 852-4835
contact@nanobiotix.com<\/a><\/p>\n

<\/a><\/u><\/td>\n

\n Investor Relations Department<\/strong>
\n
\n Ricky Bhajun<\/em>
\n
\n Director, Investor Relations<\/em>
\n
+33 (0)6 42 05 34 15
investors@nanobiotix.com<\/a><\/u><\/td>\n		\u00a0<\/td>\n<\/tr>\n
\n Media Relations<\/em>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\n
France \u2013 HARDY<\/strong>
Caroline Hardy
+33 06 70 33 49 50
carolinehardy@outlook.fr<\/u><\/a><\/p>\n<\/td>\n		Global \u2013 uncapped<\/strong>
Becky Lauer
+1 (646) 286-0057
uncappednanobiotix@uncappedcommunications.com<\/a><\/u><\/td>\n		\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n Attachments<\/strong>\n <\/p>\n